Obesity
Explore facts and recommendations for pharmacological treatments for obesity.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
Chronic Weight Management (IME content)
This video reviews the current medications approved in the US for chronic weight management, as well as their mechanisms of action.
Mechanisms in the Management of Obesity (IME Content)
View this video for a quick overview on the multiple mechanisms that have been identified in the management of obesity.
Wegovy® vs Placebo for Weight Management in Combination with IBT (STEP 3)
This video discusses STEP 3, which was a Phase 3a, 68-week, randomized, placebo-controlled, double-blind, multicenter trial conducted in 611 adult patients with obesity or overweight and at least 1 weight-related comorbidity in the US
Wegovy® vs Placebo and Ozempic® for Weight Management in Adults with Type 2 Diabetes (STEP 2)
This video discusses STEP 2, which was a Phase 3a, 68-week, randomized, placebo-controlled, double-dummy, double-blind, multicenter, multinational trial conducted in 1210 adult patients with obesity or overweight and type 2 diabetes.
Reference Guide for Patients Starting Medication for Weight Management (IME Content)
Guide cover various topics included why medications maybe needed to manage weight, setting weight loss goals with HCP, and dosing & side effects for medications approved for long-term use.
Obesity Pharmacotherapy Quick Reference Guide for HCPs (IME Content)
Reference guide covers AOM approved for long-term use, initiation & titration of pharmacologic treatment options, managing adverse events, and tips for effective communication and education for patients.
Wegovy® (semaglutide) Injection Dosing – Guidelines
Wegovy® Dosing Guidelines. Wegovy® should be initiated at a dose of 0.25 mg once weekly for 4 weeks. The dose should be increased in 4-week intervals (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) until the maintenance dose of 2.4 mg is reached.
Wegovy® (semaglutide) injection Mode of Action in Obesity
This video discusses the mechanism of action of Wegovy®
Continuing Education
Find accredited opportunities in obesity education.
Current Recommendations for Weight-Loss Medications as Part of Obesity Management (IME content)
Snapshot of why medication is a powerful tool in obesity management.
Overview of the STEP Clinical Development Program for Wegovy® (semaglutide) Injection
Information about Wegovy’s® STEP 1-4 clinical trials. These trials were built to evaluate its safety and efficacy for weight management in adult patients living with obesity and weight-related comorbidities.
Wegovy vs Placebo for Weight Management in Adults (STEP 1)
This video discusses the STEP 1 trial, which was a phase 3a, 68-week, randomized, placebo-controlled, double-blind, multinational trial conducted in 1961 adult patients with obesity, or overweight with at least 1 weight-related comorbidity.
STEP 1 Clinical Trial: Weight Management with Wegovy® (semaglutide) Injection
Results of a 68-week trial comparing weight loss while receiving Wegovy® or placebo in 1961 adults with obesity or overweight.
STEP 2 Clinical Trial: Weight Management with Wegovy® (semaglutide) Injection in Adults with Type 2 Diabetes
Findings of a 68-week trial comparing Wegovy® vs placebo vs semaglutide injection 1.0 mg in 1210 adults with overweight or obesity and Type 2 diabetes.
STEP 3 Clinical Trial: Weight Management with Wegovy® (semaglutide) Injection and Intensive Behavioral Therapy (IBT)
Outcomes of a 68-week trial comparing Wegovy® vs placebo in combination with IBT in 611 adults with obesity or overweight and at least 1 weight-related comorbidity.
STEP 4 Clinical Trial: Sustained Weight Management with Wegovy® (semaglutide) Injection
Findings of a 68-week trial comparing sustained weight management in adults with obesity or overweight and at least 1 weight-related comorbidity while receiving Wegovy® or placebo.
Obesity
Obesity
Looking for additional resources?
Explore other libraries or search the Exchange.
Additional Information
Speak to a live medical representative.
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit here to contact us, or call 1-800-727-6500.
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.
